Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares traded up 2.2% during mid-day trading on Tuesday . The stock traded as high as $6.14 and last traded at $5.99, with a volume of 1,367,637 shares. The stock had previously closed at $5.86.

Several research analysts have issued reports on the company. Zacks Investment Research upgraded Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Tuesday. Griffin Securities reiterated a “buy” rating and set a $21.00 price objective on shares of Ziopharm Oncology in a research note on Monday. Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research note on Wednesday, August 10th. Mizuho reiterated a “neutral” rating and set a $5.00 price objective (down from $7.00) on shares of Ziopharm Oncology in a research note on Monday, July 18th. Finally, Raymond James Financial Inc. assumed coverage on Ziopharm Oncology in a research note on Thursday, June 2nd. They set a “market perform” rating for the company. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Ziopharm Oncology currently has a consensus rating of “Buy” and an average target price of $9.75.

The firm’s market capitalization is $756.88 million. The firm’s 50 day moving average price is $5.27 and its 200 day moving average price is $6.75.

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.90. The company earned $1.70 million during the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology’s revenue for the quarter was up 525.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.11) EPS. Equities research analysts predict that Ziopharm Oncology Inc. will post ($0.88) EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank increased its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 3,500 shares during the period. Morgan Stanley increased its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.